Seeking Alpha (@SeekingAlpha) “Hims & Hers Health shares fell over 11% after an FDA advisory panel voted 7 to 6” — TopicDigg
Seeking Alpha
@SeekingAlpha
A global leader in crowdsourced U.S. investment research, powered by one of the largest and most vibrant investor communities.
加入 March 2009
231 正在关注 335.4K 粉丝
Hims & Hers Health shares fell over 11% after an FDA advisory panel voted 7 to 6 against adding Emideltide to the compounding 503A Bulks List.
THE IMPACT: The narrow rejection raises near-term regulatory hurdles for compounding pharmacy operators looking to offer customized peptide therapies.
FUNDAMENTALS: Core operations remain strong, supported by $2.37B in total revenue and a high 72.92% gross margin.
THE RATING: Regulatory uncertainty keeps the Seeking Alpha Quant score at a neutral HOLD.
Will $HIMS overcome these regulatory hurdles with its expanded pharmacy compounding strategy?
显示更多
